Legacy Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Legacy Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-100	Closed	-$14K	–	204
2017 Q1	$14K	Hold	100	–	–	0.02%	140
2016 Q4	$10K	Buy	+100	New	+$11.1K	0.01%	177

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Legacy Advisors's JAZZ Position: Q2 2017 in Review

Legacy Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2017, closing a stake of 100 shares — an estimated $14K sold.

Legacy Advisors first reported a position in JAZZ in Q4 2016 and held it in 2 quarters. The position peaked at $14K in Q1 2017. 319 funds tracked by Wall St. Rank hold JAZZ as of Q2 2017.

Legacy Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Legacy Advisors sold 100 Jazz Pharmaceuticals shares in Q2 2017, an estimated $14K.
Legacy Advisors first reported a position in Jazz Pharmaceuticals in Q4 2016 and held it in 2 quarters.
Legacy Advisors's Jazz Pharmaceuticals position peaked at $14K in Q1 2017.
319 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2017.

Based on Legacy Advisors's 13F filing for Q2 2017, filed 1 Nov 2017.